LETTER TO THE EDITOR

Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”

Bhaskar Rege1 · James McGrory1 · Sabina Gasper1 · David McDonnell2

Accepted: 21 September 2022 / Published online: 11 November 2022 © The Author(s) 2022

Dear Editor,

A recent article by Piena et al. [1] used integrated pharmacokinetic (PK)–pharmacodynamic (PD)–pharmacoeconomic modeling to compare costs and effects (relapses) of long-acting injectable (LAI) aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) dosing regimens in patients with schizophrenia. Because risk of relapse remains high in patients treated with antipsychotic drugs [2, 3], this important area of research can inform treatment decisions. However, clinically meaningful results from this pharmacoeconomic model depend on valid input from PK–PD modeling and simulations, and some of the assumptions underlying the PK–PD model appear to be incorrect. We therefore question the article’s pharmacoeconomic conclusions.

Input for the pharmacoeconomic analysis included simulated relapse rates from the PK–PD model for several AM and AL regimens. That model was established based on minimum plasma aripiprazole concentrations ($C_{\text{min}}$) from simulated steady-state exposures using a dichotomous hazard function with a cutoff of 95 ng/mL. The probability of relapse for each simulated patient during each dosing interval was based on whether $C_{\text{min}}$ for that cycle fell below 95 ng/mL.

The use of a binary framework based on a threshold of $C_{\text{min}} = 95$ ng/mL to estimate the probability of relapse for AL regimens is problematic for several reasons. First, Piena et al. described the 95 ng/mL threshold as “consistent with the lower boundary of the established therapeutic window for aripiprazole” [1] based on the median $C_{\text{min}}$ at steady state for the lowest effective dose of oral aripiprazole (10 mg/day) [11, 12]. They then assumed that aripiprazole exposures with a $C_{\text{min}}$ below that median value fall outside of the therapeutic window and therefore are associated with an increased risk of relapse. However, as previously noted [13], this assumption is not true. The boundary of the therapeutic window has been established based on a median value; therefore, half of all $C_{\text{min}}$ values for the effective oral aripiprazole 10 mg/day dose, by definition, fall below that threshold. Median $C_{\text{min}}$ at steady state describes one aspect of aripiprazole PK at the population level, not an absolute limit for therapeutic exposure in individual patients. Indeed, although the model-simulated aripiprazole $C_{\text{min}}$ is more likely to fall below 95 ng/mL after administration of AL 441 mg monthly or 1064 mg every 2 months compared with higher doses, both regimens have established efficacy in patients with schizophrenia [14, 15] and no clinically

This comment refers to the article available online at https://doi.org/10.1007/s40273-021-01077-8.

Bhaskar Rege
Bhaskar.Rege@alkermes.com
1 Alkermes, Inc., 852 Winter Street, Waltham, MA 02451, USA
2 Alkermes Pharma Ireland Ltd, Dublin, Ireland
meaningful efficacy differences were observed between the 441 mg and 882 mg monthly doses in a 12-week pivotal trial [14]. All AL dosing regimens provide plasma aripiprazole concentrations within the range associated with AL efficacy [6, 16, 17].

Third, the use of dichotomous hazard function for $C_{\text{min}}$ (regardless of the threshold value) is also of concern. It is well known that dichotomization contributes to loss of information. In addition, it assumes that, within a dosing cycle, the likelihood of relapse is the same whether plasma aripiprazole concentrations cross the threshold at a single timepoint or remain continuously below the cutoff value. Gaps in antipsychotic medication due to lack of adherence are associated with poor clinical outcomes in patients with schizophrenia [18, 19], but peaks and troughs in plasma drug levels over the LAI dosing interval are expected [6]. The use of a binary threshold does not take into account the differing effects on brain exposures or receptor occupancies associated with prolonged subtherapeutic exposure versus a dip in plasma drug concentration at a single timepoint.

Finally, some additional points affect the interpretation of the PK–PD analysis. The authors state that “according to expert opinion, in clinical practice, AL 441 mg and AM 300 mg are generally used only when patients do not tolerate higher doses” [1]. However, the cited source discusses AM 300 mg only [20], and that assertion is not true for AL 441 mg. On the contrary, AL can be initiated using any of the approved dosing regimens, including 441 mg monthly [17, 21]. Furthermore, Piena et al. included AL 1064 mg every 6 weeks in their analysis, which is not among the tested or approved AL dosing regimens [17]; therefore, any conclusions related to this dose are not meaningful.

In summary, because the input for the pharmacoeconomic model (probability of relapse) has no basis in AL clinical data and is not appropriate for modeling AL outcomes, no conclusions regarding AL can be drawn from the results reported. The AL 441 mg monthly and 1064 mg every 2 months dosing regimens have established efficacy in the treatment of adult patients with schizophrenia [14, 15, 21], and there is no evidence of clinically meaningful differences in efficacy between available AL doses [14]. All approved AL doses result in stable exposures that fall within the range of concentrations associated with the known efficacy of the AL 441 mg monthly and 882 mg monthly regimens [6, 16, 17]. A greater understanding of potential differences between LAI antipsychotics and their dosing regimens will be invaluable for clinicians prescribing for patients with schizophrenia; unfortunately, the Piena et al. report does not add to this understanding, especially as it relates to AL.

**Acknowledgements** Medical writing and editorial support were provided by Kathleen Dorries, PhD, of Peloton Advantage, LLC (Parsippany, NJ, USA), an OPEN Health company, and funded by Alkermes, Inc.

**Declarations**

**Funding** This work was sponsored by Alkermes, Inc. (Waltham, MA, USA).

**Conflict of interest** Bhaskar Rege, James McGrory, and Sabina Gasper are employees of Alkermes, Inc., and may be shareholders. David McDonnell is an employee of Alkermes Pharma Ireland Ltd. and may be a shareholder.

**Ethics approval and consent to participate** Not applicable.

** Consent for publication** Not applicable.

**Availability of data and material** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

**References**

1. Piena MA, Houwing N, Kraan CW, Wang X, Waters H, Duffy RA, et al. An integrated pharmacokinetic–pharmacodynamic–pharmacoeconomic modeling method to evaluate treatments for adults with schizophrenia. Pharmacoeconomics. 2022;40(1):121–31. https://doi.org/10.1007/s40273-021-01077-8.

2. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020;9:CD008016. https://doi.org/10.1002/14651858.CD008016.pub3.

3. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Heres S, Kissling W, et al. Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis. Schizophr Bull. 2022;48(4):738–40. https://doi.org/10.1093/schbul/sbac041.

4. Wang X, Raoufina A, Bihorel S, Passarell J, Malkiakaarjun S, Phillips L. Population pharmacokinetic modeling and exposure-response analysis for aripiprazole once monthly in subjects with schizophrenia. Clin Pharm Drug Dev. 2022;11(2):150–64. https://doi.org/10.1002/cpdd.1022.

5. Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 2016;9(2):169–86. https://doi.org/10.1089/eclp.2016.1121809.

6. Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017;37(3):289–95. https://doi.org/10.1097/jcp.0000000000000691.
7. Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–8. https://doi.org/10.1016/j.schres.2013.06.041.

8. Raoufinia A, Peters-Strickland T, Nylander AG, Baker RA, Eramo A, Jin N, et al. Aripiprazole once-monthly 400 mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. Int J Neuropsychopharmacol. 2017;20(4):295–304. https://doi.org/10.1093/ijnp/pyw116.

9. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192–208. https://doi.org/10.1097/01.jcp.0000117422.05703.ae.

10. Leucht S, Crippa A, Siasf S, Patel MX, Orsini N, Davis JM. Dose–response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry. 2020;177(4):342–53. https://doi.org/10.1176/appi.ajp.2019.19010034.

11. Raoufinia A, Baker RA, Eramo A, Nylander AG, Landsberg W, Kostic D, et al. Initiation of aripiprazole once-monthly in patients with schizophrenia. Curr Med Res Opin. 2015;31(3):583–92. https://doi.org/10.1185/03007995.2015.1006536.

12. Salzman PM, Raoufinia A, Legacy S, Such P, Eramo A. Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole. Neuropsychiatr Dis Treat. 2017;13:1125–9. https://doi.org/10.2147/ndt.S133433.

13. McConnell SA, Desai DN, Faldu SP, Hard ML, Wehr AY, Weiden PJ, et al. Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics. Neuropsychiatr Dis Treat. 2017;13:1815–6. https://doi.org/10.2147/ndt.S143337.

14. Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zumno J, Corey L, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76(8):1085–90. https://doi.org/10.4088/JCP.14m09741.

15. Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, et al. Efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioning to outpatient care: phase 3, randomized, double-blind, active control ALPINE study. J Clin Psychiatry. 2020;81(3):19m13207. https://doi.org/10.4088/JCP.19m13207.

16. Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Molke L. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs. 2017;31(7):617–24. https://doi.org/10.1007/s40263-017-0447-7.

17. Sommi RW, Rege B, Wehr A, Faldu S, Du Y, Weiden PJ. Aripiprazole lauroxil dosing regimens: understanding dosage strengths and injection intervals. CNS Spectr. 2022;27(3):262–7. https://doi.org/10.1177/s1092852920002072.

18. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–91. https://doi.org/10.1176/appi.ps.55.8.886.

19. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11(4):147–54. https://doi.org/10.4088/PCC.08r00612.

20. Biagi E, Capuzzi E, Colmegna F, Mascarini A, Brambilla G, Ornaghi A, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther. 2017;34(5):1036–48. https://doi.org/10.1007/s12325-017-0507-x.

21. Aristada [package insert]. Waltham, MA, USA: Alkermes, Inc.; 2021.